Lymphoma Clinical Trial
Official title:
R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma
Verified date | November 2014 |
Source | Dong-A University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
The clinical efficacy of rituximab, a chimeric monoclonal antibody targeted toward the
B-cell specific antigen CD20, was initially demonstrated in cases of follicular lymphoma
(FL), but the use of this antibody has been extended over the last few years to the majority
of subtypes of B-cell CD20 positive non-Hodgkin's lymphomas, with promising results thus
far. In MZL, small numbers of case reports have chronicled the use of rituximab as a single
agent or phase II trial combination with chemotherapeutic regimens.
The results of the rituximab maintenance phase III trial demonstrated that patients with FL
who continued to take rituximab monotherapy as a maintenance therapy after responding to an
initial course of chemotherapy combined with or without rituximab experienced longer
progression-free survival durations than did those who received no rituximab maintenance
therapy. The efficacy of maintenance treatment after first-line induction treatment with
R-chemotherapy was addressed in the international PRIMA (Primary Rituximab and Maintenance)
study, which has enrolled 1,217 patients. The first results are eagerly awaited. Although
MZL has better prognosis in TTP and OS than FL, both of them are classified as the same
category of indolent lymphoma -characterized by frequent relapse and prolonged survival.
According to the results of our survey, advanced stage MZL tends to be an indolent disease -
characterized by prolonged survival with frequent relapses. Rituximab appears to contribute
to better responses, but not in TTP. Thus, we should consider maintenance treatments for MZL
patients, to extend their response duration.
Status | Completed |
Enrollment | 48 |
Est. completion date | September 2015 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed CD20 positive marginal zone B-cell lymphomas - Ann Arbor stage III or IV - No prior chemotherapy or radiotherapy for advanced stage MZL - Tumor response after 8th cycles of R-CVP CTx = SD (Stable disease) - Performance status (ECOG) = 2 - age = 20 - At least one or more bidimensionally measurable lesion(s): = 2 cm by conventional CT/ = 1 cm by spiral CT/ skin lesion (photographs should be taken) = 2 cm/ measurable lesion by physical examination = 2 cm - Adequate renal function: serum creatinine level < 2 mg/dL (177 µmol/L) - Adequate liver functions: Transaminase (AST/ALT) < 3 X upper normal value / Bilirubin < 1.5 X upper normal value /Alkaline phosphatase < 5 X upper normal value - Adequate BM functions:ANC > 1500/uL and platelet > 75,000/uL and Hemoglobin > 9.0 g/dL unless abnormalities are due to bone marrow involvement by lymphoma - Informed consent Exclusion Criteria: - Other subtypes NHL than MZL - Large cell component >10% - Tumor response after 8th cycles CTx = PD (Progression disease) - Central nervous system (CNS) metastasis - Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri - Pregnant or lactating women, women of childbearing potential not employing adequate contraception - Other serious illness or medical conditions i. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry ii. History of significant neurologic or psychiatric disorders including dementia or seizures iii. Active uncontrolled infection (viral, bacterial or fungal infection) iv. Other serious medical illnesses - Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies) - Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Sung Yong Oh | Busan |
Lead Sponsor | Collaborator |
---|---|
Dong-A University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3 year progression free survival | Historic 3 year progression free survival rate was 60 %, expected difference 20%, power 0.80, significance 0.05 and drop rate=0.1. | 3 years after last patient enrollment | No |
Secondary | Overall survival | 5 years after last patients enrollment | No | |
Secondary | toxicity | during the Rituximab maintenance treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
N/A | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |